SOHO 2021 | Tailored therapy in Waldenström’s macroglobulinemia
Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, explains how tailored therapy is currently being used to manage Waldenström’s macroglobulinemia, commenting on the need for more studies investigating optimal sequencing. Dr Castillo explains the various factors that need to be taken into consideration whilst determining the optimum therapy, such as the toxicity profiles of the agents and potential issues with administration. In the case of chemoimmunotherapy, issues with infusions, cytopenias, and the risk of developing secondary myeloid neoplasms need to be considered. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics.
